Erythromycin (Ery), co-amoxiclav (Co-amx), and combined treatments v placebo (Pl) for the composite outcome measure of death, chronic lung disease, or major cerebral abnormality in neonates of women who had pPROM*
| Comparison | Event rates | RRR (95% CI) | NNT |
|---|---|---|---|
| *pPROM = preterm, prelabour rupture of fetal membranes. Other abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article. | |||
| Ery v Pl | 12.7% v 15.2% | 16.4% (−2.0 to 31.5) | Not significant |
| Co-amx v Pl | 13.5% v 15.2% | 10.9% (−8.2 to 26.7) | Not significant |
| Combined v Pl | 14.0% v 15.2% | 7.5% (−12.2 to 23.7) | Not significant |